Community/Retail

At 1 month, a 50-µg booster dose of mRNA-1273.214 had a potent neutralizing antibody response against the Omicron variants in all individuals, regardless of prior infection.

This month features Ozempic, Igalmi, and Triumeq PD.

Levetiracetam is an anticonvulsant used to treat epileptic seizures.

Dual action for neuropathy and neuralgia pain relief as well as for use in diabetes-related nerve pain and shingles.

The FDA approved the first vaccine for dengue disease in May 2019.

The Sanofi-GSK vaccine demonstrated a favorable safety and tolerability profile throughout stage 1 and stage 2 of the VAT08 trial, according to the researchers.

As we mark the second anniversary of Bostock v. Clayton County this month, let’s remember to treat each other with dignity, empathy, and respect, while we work together for a safer and more tolerant workplace.

Clinical evaluation dictates the need for preventive therapy and advice on exercising and participation in competitive sports, according to the European Society of Cardiology.

Submission is based on phase 2 study results evaluating atogepant in adults who met the primary endpoint of a statistically significant reduction from the baseline compared with a placebo.

We spoke with Carlie Traylor, PharmD, of the National Community Pharmacy Association to learn about a fellowship program offered by NCPA and CPESN

Venlafaxine Extended-Release (Effexor XR) is indicated for the treatment of major depressive disorder, generalized anxiety disorder, social anxiety disorder, and panic disorder.

Maty's All Natural Acid and Indigestion Relief is an alternative to traditional antacid tablets to relieve indigestion and heartburn.

Suzanne Soliman, PharmD, BCMAS welcomes Sonia T. Oskouei, PharmD, BCMAS, DPLA to discuss biosimilars within the pharmacy industry.

This is the first RSV vaccination candidate to show clinically meaningful and statistically significant efficacy in adults aged 60 years and older.

Amy Cadwallader, PhD, director of Regulatory and Public Policy Development at US Pharmacopeia (USP), discusses how medicine quality and the medicines supply chain can affect antimicrobial resistance (AMR).

The impact of the pandemic on the mental health of health care workers, including pharmacists and pharmacy staff, has been well documented.

Kai Zhao, PhD, director of the Nasal Physiology and Therapeutic Center in the Department of Otolaryngology at Ohio State University College of Medicine, discusses his research investigating the persistence of taste and smell loss among patients who have been infected and reinfected with COVID-19.

Stephanie Mason believes that pharmacists should expect their involvement in glycemic management to increase in the near future.

Hydrogel Burn Pads provide cooling relief for minor burns and absorbs fluid to prevent infection.

Insurers are refusing to cover new, highly effective anti-obesity drugs, but some prescribers are getting around the issue.

Vaxneuvance was approved for an expanded indication by the FDA on June 22, 2022, for active immunization in children 6 weeks of age and older.

This month's OTC product news features contact lenses for astigmatism, supplements, and children's probiotics.

But investigators find that individuals who had shingles that spread to the central nervous system had nearly twice the risk of developing mental deterioration, though it is rare.

Analysis shows that individuals who received treatment within 3 days of symptom onset with tixagevimab and cilgavimab reduced their risk by 88% compared with the placebo.

The Opioid and Naloxone program at North Dakota State University School of Pharmacy aims to make a difference.

Acuvail ophthalmic solution is a nonsteroidal, anti-inflammatory indicated for the treatment of pain and inflammation following cataract surgery.

Arthriten may offer relief from minor arthritis pain.

The survey results come as the ACIP evaluates data to provide guidance for flu vaccines in older adults.

Jardiance shows reduction of 50% compared with dipeptidyl peptidase-4 inhibitors and 30% compared with glucagon-like peptide 1 receptor agonists.